Innovent Biologics Inc
Research Innovent Biologics Inc (6IB) on Bullrun: market cap EUR 20.17B, P/E 193.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6IB
- ExchangeF
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 20.17B
- P/E193.1
- Financial periodFY2025
- RevenueCNY 13.04B
- Revenue growth38.4%
- Net incomeCNY 813.57M
- Free cash flowCNY 9.32B
- Gross margin86.5%
Valuation Snapshot
latest market cap is EUR 20.17B; P/E is 193.1.
Peer valuation comparison
Latest P/E is 193.07x versus a Healthcare sector median of 24.46x (689.3% above).
Latest P/E is 193.07x versus a China median of 10.67x (1709.0% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 13.04B | CNY 813.57M | CNY 9.32B | 86.5% | 0.47 | CNY 17.34B | CNY 2.82B | CNY 19.36B |
| FY2024 | CNY 9.42B | -CNY 94.63M | -CNY 418.39M | 84.0% | -0.06 | CNY 7.51B | CNY 2.83B | CNY 13.12B |
| FY2023 | CNY 6.21B | -CNY 1.03B | -CNY 1.24B | 81.7% | -0.66 | CNY 2.75B | CNY 3.62B | CNY 12.53B |
| FY2022 | CNY 4.56B | -CNY 2.18B | -CNY 3.30B | 79.6% | -1.46 | CNY 1.02B | CNY 3.23B | CNY 10.73B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 20.17B | 193.1 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Innovent Biologics Inc
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Innovent Biologics Inc's market cap?
Innovent Biologics Inc's market capitalization is EUR 20.17B.
What is Innovent Biologics Inc's P/E ratio?
Innovent Biologics Inc's price-to-earnings (P/E) ratio is 193.1.
What does Innovent Biologics Inc do?
Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People's Republic of China, the United States, Europe, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies and other drugs for the treatment of oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases.